UNSPSC 51282323: Erythromycin oxime

This classification denotes a macrolide antibiotic C37H68N2O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10W452CMTZ, chemically known as erythromycin, 9-oxime, but more generally known as erythromycin oxime, which bears US NIH Compound Identifier 6537896. Most nations, for tariff and trade purposes, schedule erythromycin oxime under HS 29415000 and SITC 54139. As of Q4 2014, ERYTHROMYCIN OXIME remains US FDA's Preferred Term for this commodity.

Erythromycin oxime bears US NLM identifiers UMLS ID C0207096 and NCI Concept Code C87758. SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=NO)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.

UNSPSC 51282323 Erythromycin oxime is a Commodity code that nominally describes a specific pharmaceutical compound, but recent state and local solicitations do not target this ingredient directly. Instead, the opportunities tagged under this code reflect broader pharmaceutical and medical supply procurement — including naloxone and drug deactivation systems for public health initiatives, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals distributed through cooperative purchasing vehicles. The issuing bodies span county health departments, state health and human services commissions, municipal fire departments, and multistate cooperative purchasing alliances. The mismatch between the code's narrow pharmaceutical-ingredient name and the actual scope of work being solicited suggests the code is either being applied inconsistently across jurisdictions or is serving as a catch-all classification for pharmaceutical and medical supply procurement that does not fit narrower commodity definitions.

Recent activity appears concentrated in Florida and Texas, with regional multi-state programs anchored in Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, due July 26, 2023 (note: date conflict in source), with quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs for a Therapeutic Pharmacy Initiative. The City of Tampa issued ITB 26P00145 in March 2026 for medical and first aid supplies including respiratory equipment, monitoring electrodes, and consumables for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000 and a 5% small local business enterprise discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with distribution through authorized wholesalers and contract effectiveness July 1, 2026. Given the code's narrow definition and the lack of direct erythromycin-oxime procurement signals, activity under this code warrants verification against intended commodity scope before resource commitment.